EN
抗体药类似物
Research Grade Anbenitamab
All
  • CatalogTD-HY286106
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsBispecific,KN026,KN-026,CAS:2367012-88-0
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Anbenitamab


Catalog No. TD-HY286106
Species reactivity Human
Applications Research Grade Biosimilar
Host species Humanized
Isotype IgG1;Kappa;Kappa
Expression system Mammalian Cells
Clonality Monoclonal
Target p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession P04626
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names Bispecific,KN026,KN-026,CAS:2367012-88-0
Background Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research.
Note For research use only. Not for use in clinical or therapeutic applications.